U.S. markets closed

GT Biopharma, Inc. (GTBP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.98-0.01 (-0.06%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close17.99
Open17.66
Bid17.00 x 1000
Ask18.10 x 1000
Day's Range17.34 - 18.05
52 Week Range2.04 - 19.73
Volume290,774
Avg. Volume564,141
Market Cap379.876M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-7.59
Earnings DateMay 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GT Biopharma to Present at Raymond James Human Health Innovation Conference
    PR Newswire

    GT Biopharma to Present at Raymond James Human Health Innovation Conference

    GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it will provide a corporate update at the upcoming Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.

  • GT Biopharma to be Added to the Russell 2000® Index
    PR Newswire

    GT Biopharma to be Added to the Russell 2000® Index

    GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.

  • GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET
    PR Newswire

    GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET

    GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology, TriKE™, for the treatment of cancer and infectious diseases, today announced that it will be hosting a call with Dr. Jeffrey S. Miller and GT Biopharma on Wednesday, May 19th at 4:00 PM Eastern Time.